Clear Eyes Recalled 39,060 Bottles of Maximum Itchy Eye Relief for a “Lack of Assurance of Sterility.” One Lot, One Expiration Date, a Refund at the Register — and, as of Today, No Lawsuit. What the Class II Label Actually Means, and Why Eye Drops Are the One Product Where That Phrase Gets a Second Look.
The FDA’s enforcement report lists recall D-0766-2026: Prestige Brands Holdings of Tarrytown, New York, voluntarily pulled Clear Eyes Maximum Itchy Eye Relief, lot 2552A, expiration September 30, 2027, from nationwide distribution on July 29, 2026; the agency classified it Class II on August 14 and published it on August 19. No adverse events have been reported. Search demand for “clear eyes recall” hit the top of our page-candidate monitor on September 2, the day Top Class Actions covered the recall, and the question people are asking — is there a lawsuit? — has a plain answer: not that we can find. Here is the record, the meaning of the words on it, and what a claim would need that this recall does not yet supply.
By Settlement Insight Data Desk ·

What was recalled, exactly
| Field (FDA enforcement report) | Entry |
|---|---|
| Recall number | D-0766-2026 |
| Product | “CLEAR EYES Maximum Itchy Eye Relief, 0.5 fl oz (15 mL) per dropper bottle, Sterile” — NDC 67172-999-01, UPC 6 78112 65920 3 |
| Lot / expiration | Lot 2552A, Exp 09/30/2027 |
| Quantity | 39,060 15 mL bottles |
| Reason | “Lack of assurance of sterility. The recall is due to potential contamination” |
| Recalling firm | Prestige Brands Holdings, Tarrytown, NY (label: distributed by Medtech Products Inc., a Prestige Consumer Healthcare company) |
| Distribution | Nationwide in the USA |
| Dates | Initiated July 29, 2026; classified August 14; reported August 19, 2026 |
| Type / status | Voluntary, firm initiated; Ongoing |
Check the box and the bottle for the lot number. Other Clear Eyes products, and other lots of Maximum Itchy Eye Relief, are not part of this recall. It is an over-the-counter decongestant-astringent drop sold for allergy itch; FDA’s enforcement listings for the same UPC give the active ingredients as glycerin, naphazoline hydrochloride and zinc sulfate.
“Class II” and “lack of assurance of sterility”: what the words mean
FDA sorts recalls into three classes by the harm a product could do. Under 21 C.F.R. § 7.3(m), Class II is “a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.” Class I is reserved for a reasonable probability of serious harm or death; Class III is for products unlikely to cause any. Class II is the middle category.
“Lack of assurance of sterility” is a manufacturing finding, not a laboratory one. It means the company could not demonstrate that the lot was sterile — a failed or missing control, a process deviation — not that bacteria or fungi were found in bottles. NBC and CBS, reporting on the FDA listing, described it the same way: the product is not known to be contaminated, but the manufacturer cannot say it is not. Prestige Consumer Healthcare did not immediately respond to CBS News’s request for comment. A company spokesperson told NBC News the next day that no injuries had been reported to date and that “although the affected product was not confirmed to be contaminated, we initiated this voluntary recall out of an abundance of caution.”
The phrase is not new to this brand. FDA’s enforcement database holds 19 Clear Eyes entries. In July 2019, Altaire Pharmaceuticals of Aquebogue, New York recalled Clear Eyes Redness Relief lots for the identical reason, “Lack of Assurance of Sterility,” and Medtech Products recalled fourteen Clear Eyes displays and lots — more than 13 million bottles across those entries, though the display entries overlap with the individual lots they contain — for “CGMP Deviations” at a manufacturing facility. In February 2023, Teva recalled 715,632 bottles of Clear Eyes Once Daily (olopatadine) for a failed impurities specification. All of those recalls were completed and are unrelated to lot 2552A, but they explain why regulators treat sterility paperwork on eye drops as seriously as a positive culture.
Why eye drops get the second look
Eye drops go onto the one surface where a contaminant does not need to survive the stomach. The reference case is the 2023 outbreak tied to EzriCare and Delsam Pharma artificial tears, made by an Indian manufacturer, Global Pharma Healthcare, and contaminated with an extensively drug-resistant strain of Pseudomonas aeruginosa. By the CDC’s May 2023 update, that outbreak had reached 81 patients in 18 states, with four deaths, 14 people with vision loss and four surgical removals of an eye. That is what a contaminated eye drop can do, and it is why an agency listing that says only “potential contamination” still gets covered nationally. It is also the difference between that case and this one: there, a pathogen was found and matched to patients; here, nothing has been found and no one has reported being hurt.
Refund, not a claim form — and what a lawsuit would need
There is no settlement, no claim form and no fund. The remedy, per the recall notice as quoted by Top Class Actions, is to “discontinue use of the product and return it to the place of purchase for a refund”; the company’s consumer line is 877-274-1787. Keep the box or a photo of the lot number. We searched the CourtListener RECAP archive for cases naming Clear Eyes, Prestige or Medtech and found nothing filed in 2026 — a finding limited by RECAP’s coverage, which is thin for state courts — and no news report of a class action as of September 3, 2026.
Recalls sometimes turn into lawsuits, and it is worth being precise about when. A consumer class action over a recalled over-the-counter product usually alleges economic loss — you paid for a sterile product and got one that could not be shown to be sterile — and such cases tend to settle for refund-sized amounts, if they survive at all when a refund is already on offer. A personal-injury claim is different in kind: it needs an injury (an infection diagnosed by a doctor), a causal link (a culture matching an organism in the product, or at minimum documented use of the recalled lot before onset), and the bottle or its lot number. If you used lot 2552A and then developed an eye infection, see an eye doctor first, keep the bottle, and ask the clinic to culture it. Without that chain there is no case; with it, there may be.
The Data Behind This Story
- Recall number
- D-0766-2026 (FDA drug enforcement report)
- Product
- Clear Eyes Maximum Itchy Eye Relief, 0.5 fl oz (15 mL) dropper bottle — NDC 67172-999-01, UPC 6 78112 65920 3
- Lot / expiration
- Lot 2552A, Exp 09/30/2027
- Quantity
- 39,060 bottles, nationwide (USA)
- Reason
- “Lack of assurance of sterility. The recall is due to potential contamination”
- Classification
- Class II — “may cause temporary or medically reversible adverse health consequences” (21 C.F.R. § 7.3(m))
- Dates
- Initiated July 29, 2026 · classified August 14, 2026 · reported August 19, 2026 · status Ongoing
- Recalling firm
- Prestige Brands Holdings, Tarrytown, NY (Medtech Products Inc. / Prestige Consumer Healthcare)
- Injuries reported
- None reported to date, per a Prestige spokesperson quoted by NBC News (August 21, 2026) and Top Class Actions (September 2, 2026)
- Remedy
- Stop using; return to the place of purchase for a refund (recall notice, as quoted by Top Class Actions; hotline 877-274-1787) — no claim form, no settlement
- Lawsuit
- None found — CourtListener RECAP search and news search, September 3, 2026
- Prior Clear Eyes recalls
- July 2019: Altaire Pharmaceuticals (Redness Relief, “Lack of Assurance of Sterility”) and Medtech Products (14 entries, CGMP deviations); February 2023: Teva (Clear Eyes Once Daily, 715,632 bottles, failed impurities specification) — all completed
- Source: openFDA drug enforcement API, record D-0766-2026, queried September 3, 2026: api.fda.gov/drug/enforcement.json?search=product_description:%22Clear+Eyes%22 — every field in the table is quoted from that record (recall_initiation_date 20260729, center_classification_date 20260814, report_date 20260819, product_quantity “39,060 15mL-bottles”, code_info “Lot 2552A, Exp 09/30/2027”). The same query returns the 2019 Altaire (D-0487-2020, D-0489-2020, D-0490-2020), the 2019 Medtech (D-1822-2019 through D-1835-2019) and the 2023 Teva (D-0469-2023) entries.
- Source: 21 C.F.R. § 7.3(m) — recall classification definitions (Class I, II, III).
- Source: CBS News, “Clear Eyes eye drops recalled nationwide over contamination risk,” Mary Cunningham, August 20, 2026 — company did not respond to a request for comment; no adverse events reported.
- Source: NBC News, “Eye drops sold nationwide recalled over possible contamination, FDA reports,” August 21, 2026 — description of “lack of assurance of sterility”; Prestige spokesperson quoted (no injuries reported to date; “out of an abundance of caution”).
- Source: Top Class Actions, September 2, 2026, “Clear Eyes recalls 39K bottles…” — quotes the recall notice (discontinue use, return to the place of purchase for a refund, hotline 877-274-1787) and notes that no lawsuit has been filed (attributed).
- Source: CIDRAP / CDC outbreak updates, May 2023 — EzriCare/Delsam Pharma artificial tears: 81 patients in 18 states, 4 deaths, 14 with vision loss, 4 enucleations.
- Source: CourtListener RECAP search, September 3, 2026: “Clear Eyes” AND (Prestige OR Medtech), sorted by filing date — no 2026 docket. Coverage caveat: RECAP is incomplete, especially for state courts.
- Source: Our page-candidate monitor (news-monitor/pagefinder), September 2–3, 2026 — search-demand score for “clear eyes recall” at its maximum, based on autocomplete evidence (“clear eyes recall,” “clear eyes recall 2026”); no Google Trends entry.
Journalists: these figures are free to cite with attribution to Settlement Insight. Custom data pulls: press@settlementinsight.com.